Rapid Micro Biosystems (RPID) risk factors, FY2024 10-K

Risks Related to Our Financial Position and Need for Capital

1. 01We have incurred significant losses since inception, we expect to incur losses in the future and we may not be able to achieve and maintain positive cash flow and profitability
2. 02Our limited operating history makes it difficult to evaluate our future prospects and the risks and challenges we may encounter
3. 03Our business depends on the commercial success of our Growth Direct platform, which may not be achieved or maintained
4. 04Our operating results have fluctuated significantly in the past and will fluctuate significantly in the future, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations
5. 05We have in the past and may in the future fail to meet our publicly announced guidance or other expectations about our business and future operating results, which could adversely affect our business, reputation and financial results and cause our stock price to decline
6. 06If we cannot maintain the level of sales of our Growth Direct systems or the sales of our consumables and services to existing customers declines, our future operating results would be adversely affected
7. 07We may need or otherwise decide to raise additional capital to fund our existing operations, improve our platform or develop and commercialize new products or expand our operations

Risks Related to Our Business and Strategy

1. 08Our business relies heavily on establishing and maintaining our position in the market as a leading provider of automated MQC testing
2. 09We may not be successful in expanding our business with existing customers and driving adoption of our solutions with new customers
3. 10We may not successfully expand our Growth Direct platform to customers who manufacture cell and gene therapies
4. 11The size of the markets and forecasts of market growth for automated MQC testing and other of our key performance indicators are based on a number of complex assumptions and estimates, and may be inaccurate
5. 12New product development involves a lengthy and complex process and we may be unable to develop or commercialize products on a timely basis, or at all
6. 13In addition, if we are unable to generate additional data and insights from our existing Growth Direct platforms, then we may not be able to advance these programs as quickly, or at all, or without significant additional investment, all of which could have a material adverse effect on our product development efforts
7. 14Our customers use our Growth Direct platform as part of their quality-control workflow, which is subject to regulation by the FDA and other comparable regulatory authorities
8. 15If we are unable to manage our inventory and support demand for existing and future products on the Growth Direct platform, our business could suffer
9. 16We have limited experience in marketing and sales, and if we are unable to successfully market our products to new and existing customers, address our customers’ needs or to expand our customer base, our business may be adversely affected
10. 17Our Operational Efficiency Program, including a reduction in workforce, may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could disrupt our business
11. 18We may be unable to manage our future growth effectively, which could make it difficult to execute our business strategy
12. 19If we cannot compete successfully, we may be unable to increase or sustain our revenue, or achieve and sustain profitability
13. 20We must develop new products, adapt to rapid and significant technological change and respond to introductions of new products by competitors to remain competitive
14. 21The Growth Direct platform may contain undetected errors or defects or may not otherwise meet the expectations of our customers, which means our business, financial condition, results of operations and prospects could suffer
15. 22Direct systems under warranty. Our failure to prevent or adequately address any of foregoing risks could have a material adverse effect on our business, operating results and financial condition
16. 23Potential product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop
17. 24If we lose key management, cannot recruit qualified employees, directors, officers or other significant personnel or experience increases in our compensation costs, our business may be materially harmed
18. 25We depend on our information technology systems, and any failure of these systems could harm our business
19. 26Cybersecurity incidents and data breaches, data loss and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation
20. 27Like many companies, we use artificial intelligence and machine learning (AI) technologies, including generative AI, to efficiently grow and manage our business. These technologies have increasingly been the focus of attention for lawmakers and regulators around the globe
21. 28We may evaluate strategic opportunities for our business, including through acquisitions, joint ventures or investments in other companies or technologies that could negatively affect our operating results, dilute our stockholders’ ownership, increase our debt or cause us to incur significant expense
22. 29We may not realize the intended benefits of our strategic partnerships and other collaborations, and such relationships may introduce additional risks to our business
23. 30Repair or replacement costs due to warranties we provide on our Growth Direct systems could have a material adverse effect on our business, financial condition and results of operations
24. 31We do not carry insurance for all categories of risk that our business may encounter and our policies have limits and significant deductibles. Some of the policies we currently maintain include general liability, property, umbrella, cybersecurity, and directors’ and officers’ insurance
25. 32International expansion of our business exposes us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States
26. 33Global economic and political instability and geopolitical events could adversely affect our business, financial condition or results of operations
27. 34Our employees, consultants and collaborators may engage in misconduct or other improper activities

Risks Related to Manufacturing and Supply

1. 35If our primary manufacturing facility or development facility becomes damaged or inoperable or we are required to vacate one or both facilities, our ability to conduct and pursue our manufacturing and/or development efforts would be jeopardized
2. 36Our manufacturing operations are dependent upon third-party suppliers, including single-source suppliers, making us vulnerable to supply shortages and price fluctuations, which could harm our business
3. 37We forecast sales to determine requirements for components and materials used in our products, and if our forecasts are incorrect, we may experience delays in shipments or increased inventory costs
4. 38Shipping is a critical part of our business and any changes in our shipping arrangements or damages or losses sustained during shipping could adversely affect our business, financial condition, results of operations and prospects
5. 39We use biological and hazardous materials that require considerable expertise and expense for handling, storage and disposal and may result in claims against us

Risks Related to Our Intellectual Property

1. 40Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time
2. 41The United States government may exercise certain rights with regard to certain of our inventions developed using government funding
3. 42If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected and our business could be harmed
4. 43We may not be able to protect our intellectual property rights throughout the world
5. 44We may not be able to protect and enforce our trademarks and trade names, or build name recognition in our markets of interest thereby harming our competitive position
6. 45We may be subject to claims challenging the inventorship and ownership of our patents and other intellectual property
7. 46We may be involved in litigation claiming that we have infringed on a third party’s intellectual property, which could be time consuming and costly and may adversely affect our business, financial condition, results of operations and prospects
8. 47We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time consuming and unsuccessful
9. 48Our use of open-source software could compromise our ability to offer our services and subject us to possible litigation

Risks Related to Our Common Stock

1. 49The market price of our Class A common stock has been and may continue to be volatile and fluctuate substantially, which could result in substantial losses for our stockholders
2. 50If our Class A common stock is delisted from the Nasdaq Stock Market, the liquidity of our Class A common stock would be adversely affected and the market price of our common stock could decrease
3. 51Sales of a substantial number of shares of our Class A common stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares, could depress the market price of our Class A common stock
4. 52An active trading market for our Class A common stock may not be sustainable
5. 53Our executive officers, directors and principal stockholders, if they choose to act together, have the ability to control all matters submitted to stockholders for approval
6. 54The dual class structure of our common stock and the option of the holders of shares of our Class B common stock to convert into shares of our Class A common stock may limit our Class A stockholders’ ability to influence corporate matters
7. 55We are an “emerging growth company,” and a "smaller reporting company," and the reduced disclosure requirements applicable to us may make our Class A common stock less attractive to investors
8. 56If we fail to maintain effective internal control over financial reporting and effective disclosure controls and procedures, we may not be able to accurately report our financial results in a timely manner or prevent fraud, which may adversely affect investor confidence in our company
9. 57Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
10. 58Provisions in our restated certificate of incorporation and amended and restated bylaws and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management
11. 59We have been, and may continue to be, subject to the actions of activist stockholders or unsolicited acquisition proposals, which could cause us to incur substantial costs, divert management’s and the board’s attention and resources, and have an adverse effect on our business and stock price
12. 60Our restated certificate of incorporation designates specific courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us
13. 61Our ability to use our net operating losses and research and development tax credits to offset future taxable income or income tax liabilities is subject to certain limitations
14. 62There is increased attention to environmental, social and governance matters that may impact our business
15. 63Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, would be stockholders’ sole source of gain
16. 64If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline, even if our business is doing well
17. 65We could be subject to securities class action litigation
18. 66Conditions in the banking system and financial markets, including the failure of banks and financial institutions, could have an adverse effect on our operations and financial results